Research report
A research report is the sourced material a domain
dossier is synthesized from — generated on a plan and a cadence, one topic per file.
A report carries no confidence tags. Its bracketed markers say who might have
an incentive to shade a line; none of them says anyone checked it. To reach a score, a line has
to be drafted onto a candidate as unverified and pass the Verifier or the
Corroborator, like everything else.
Section clinical-evidence · Version 2026-09-01 · Cadence quarterly · Evidence class mixed · Sources 7 · Supersedes none
Domain: feline-ckd-subcutaneous-fluid-therapy · Scope: Peer-reviewed literature (PubMed/PMID, including full text reached via a
Sourcing: Rests on one primary-source full-text retrieval that resolves a gap the
The domain dossier recorded the ISFM guideline's full text as blocked twice (SAGE and ResearchGate, both HTTP 403); this pass reached it through its PMC mirror and can now quote the actual recommendation directly rather than a search-result paraphrase: 75–150 mL every 1–3 days, for IRIS stages 3–4, with no evidence grade or supporting trial citation attached to that specific line [1]. The AAHA 2024 Fluid Therapy Guidelines for Dogs and Cats is confirmed to exist as a peer-reviewed practice guideline with a resolvable DOI, but its publisher page still refuses this report's fetch (HTTP 403), so its feline-CKD-specific content remains unread beyond the general abstract [2]. No randomized or controlled trial measuring subcutaneous fluid therapy's effect on any feline CKD clinical outcome — survival, biochemical control, or hospitalization — was located by any of six independent PubMed query strings run this pass, and ClinicalTrials.gov (a human registry, structurally) returns zero records for the condition at all. This negative result is not for want of an active feline-CKD trial landscape: three separate randomized, placebo- or control-arm trials of other interventions (vitamin E, N-acetylcysteine, an oral adsorbent) were published or indexed in 2024–2026, each with a stated n and a measured biochemical or survival endpoint [5][6][7] — subcutaneous fluid therapy has none of that. Two independent owner surveys, different populations and years, agree that home subcutaneous fluid administration is a common, guideline-linked practice that scales with disease severity [3][4].
_Baseline (v1). No prior version; this establishes the starting point for future diffs._
The domain dossier's own account records two direct full-text attempts at this document, both returning HTTP 403. This pass reached the same article through its PMC mirror (PMID 26936494 = PMC11148907) and can quote the specific recommendation rather than a secondary paraphrase: "Repeated subcutaneous fluid therapy (75–150 ml every 1–3 days) can be used on an outpatient basis... or by owners at home to maintain hydration. This is most commonly employed in cats with advanced (stages 3 and 4) CKD, but should be considered on a case-by-case basis. Cats should be carefully monitored to ensure there is clinical benefit and to avoid overhydration" [1] [single-source]. The panel's own abstract states generally that it "graded the quality of evidence for different interventions," but no distinct evidence grade or cited supporting trial appears attached to this specific recommendation in the text retrieved [1] [single-source] — a caveat rather than a confirmed absence, since this pass's fetch tool returns a processed excerpt of a long article and a grading table elsewhere in the document cannot be ruled out from what was retrieved.
PubMed indexes "2024 AAHA Fluid Therapy Guidelines for Dogs and Cats" as a practice guideline (PMID 38885492), and its abstract states the guidelines' general scope: "practical fluid therapy strategies for patients with various common disorders," alongside resuscitation, rehydration and maintenance recommendations generally [2]. A DOI (10.5326/jaaha-ms-7444) resolves to the publisher's page at jaaha.kglmeridian.com, but that page returned HTTP 403 to this pass's fetch — the same class of access failure the domain dossier already records for aaha.org's own FAQ page [2] [paywalled]. Whether AAHA's guideline specifies a volume, frequency, or IRIS-stage threshold for feline CKD subcutaneous fluids independently of ISFM's figure is therefore not established by this pass — not contradicted, not confirmed, simply unread.
Six PubMed query strings run this pass — "subcutaneous fluid therapy chronic kidney disease cats," "randomized controlled trial fluid therapy cats chronic kidney disease," "subcutaneous fluid administration survival cats renal," "chronic subcutaneous fluid administration cats azotemia creatinine outcome," "subcutaneous fluids cats renal quality of life effect," and "does subcutaneous fluid therapy slow progression cats kidney" — returned no randomized or prospective controlled trial measuring subcutaneous fluid therapy's effect on any CKD clinical outcome. A seventh query against ClinicalTrials.gov for condition "feline chronic kidney disease" returned zero registered records, which is expected given that registry's human-research scope rather than a veterinary-specific negative, but it forecloses that route as a check either way. This reproduces, independently and with different query strings, the domain dossier's own earlier "none found" conclusion for this same question rather than contradicting it.
Not established. No source retrieved in this pass or in the domain dossier's own prior pass reports a measured effect size — on survival, azotemia, hydration marker, or quality-of-life score — for subcutaneous fluid therapy against any comparator (no fluids, a different volume, a different route). This is a stated absence, not a search failure: it follows directly from the prior paragraph's negative trial search.
The absence above is not for lack of an active feline-CKD trial pipeline. Three separate randomized, placebo- or control-arm trials of other interventions were published or indexed in 2024–2026: a double-blind, placebo-controlled trial of vitamin E supplementation (34 CKD cats across IRIS stages 1–4, 24 weeks, plasma oxidative-stress markers and survival as endpoints) concluded "vitamin E supplementation as an addition to standard therapy does not prolong survival in feline CKD" [5] [single-source]; a double-blind, placebo-controlled trial of intravenous N-acetylcysteine in 50 cats with azotemic CKD (IRIS stages 2–4) undergoing acute-on-chronic exacerbation found significantly lower day-8 creatinine (4.01 vs 6.44 mg/dL, P<0.001) and SDMA (16.5 vs 27 µg/dL, P=0.04) in the treatment arm [6] [single-source]; and a two-centre, randomized pilot trial of the oral adsorbent Renaltec in 19 cats with IRIS stage 2–3 CKD over six months found lower indoxyl sulfate and urine protein:creatinine ratio in the treatment group at six months, while explicitly cautioning "given the pilot nature of the study, these findings should be interpreted with caution" [7] [single-source]. None of these three trials tests subcutaneous fluid therapy, and none was found to reference it as a comparator arm.
Two surveys, different countries and years, independently support the same qualitative pattern — that home subcutaneous fluid administration is a common, guideline-linked practice whose use scales with disease severity — though their specific percentages come from different populations and are not directly comparable. A 2025 Portugal-based caregiver survey (n=405 respondents caring for a cat with CKD) found subcutaneous fluid therapy administered at home by 205 of 405 (50.6%) respondents, and reported that "clinical signs and proteinuria, the need for medication and nutraceuticals/supplements, the administration of erythrocyte-stimulating agents and subcutaneous fluids, and the monitoring frequency were higher (P<0.05) in cats at late IRIS CKD stages" [3] [single-source]. A 2018 US-majority survey (n=468 owners of cats already prescribed fluids, 75% US-based per the domain dossier's own reading) found 399 of 468 (85%) gave subcutaneous fluids [4] [single-source]. The two figures are not a like-for-like comparison — Portugal's denominator is all CKD caregivers surveyed, the 2018 study's denominator is owners whose cats had fluids discussed or prescribed — but both independently point the same direction: administration is common and rises with disease severity, not a fixed or universal practice.
[1] Sparkes AH, Caney S, Chalhoub S, Elliott J, Finch N, Gajanayake I, Langston C, Lefebvre HP, White J, Quimby J. "ISFM Consensus Guidelines on the Diagnosis and Management of Feline Chronic Kidney Disease" — Journal of Feline Medicine and Surgery (published 2016, month not given in the PubMed record; accessed 2026-09-01). PMID 26936494 / PMC11148907, full text read via https://pmc.ncbi.nlm.nih.gov/articles/PMC11148907/ [guideline] [2] "2024 AAHA Fluid Therapy Guidelines for Dogs and Cats" — Journal of the American Animal Hospital Association (published 2024-07-01; accessed 2026-09-01). PMID 38885492; DOI 10.5326/jaaha-ms-7444 — https://doi.org/10.5326/jaaha-ms-7444 (resolves to jaaha.kglmeridian.com, which returned HTTP 403 to this pass's fetch; abstract retrieved via PubMed efetch instead) [guideline] [3] "Caregivers' perspectives on feline chronic kidney disease in Portugal: a questionnaire-based study" — Journal of Feline Medicine and Surgery (published 2025, month not given in the PubMed record; accessed 2026-09-01). PMID 41398709 — https://pubmed.ncbi.nlm.nih.gov/41398709/ [peer-reviewed] [4] Cooley CM, Quimby JM, Caney SM, Sieberg LG. "Survey of owner subcutaneous fluid practices in cats with chronic kidney disease" — Journal of Feline Medicine and Surgery (published 2018-10-01; accessed 2026-09-01). PMID 28948902 — https://pubmed.ncbi.nlm.nih.gov/28948902/ [peer-reviewed] [5] "Supplementation of vitamin E as an addition to a commercial renal diet does not prolong survival of cats with chronic kidney disease" — BMC Veterinary Research (published 2024-07-10; accessed 2026-09-01). PMID 38987749 — https://pubmed.ncbi.nlm.nih.gov/38987749/ [peer-reviewed] [6] "N-acetylcysteine reduces serum creatinine, blood urea nitrogen, symmetric dimethylarginine and urine protein to creatinine ratio in cats with chronic kidney disease: a double-blind, placebo-controlled clinical trial" — BMC Veterinary Research (published 2026-02-03; accessed 2026-09-01). PMID 41630014 — https://pubmed.ncbi.nlm.nih.gov/41630014/ [peer-reviewed] [7] "Evaluation of the effect of Renaltec in cats with IRIS stage 2 and 3 chronic kidney disease" — Journal of Feline Medicine and Surgery (published 2026-03-01; accessed 2026-09-01). PMID 41378759 — https://pubmed.ncbi.nlm.nih.gov/41378759/ [peer-reviewed]
Well established: That home subcutaneous fluid administration is a common, guideline-linked practice for feline CKD whose reported use rises with disease severity rests on two independent, non-affiliated surveys with different populations and years [3][4] — the qualitative pattern is stated plainly above; each survey's specific percentage remains individually marked [single-source] because the two are not measuring the same denominator.
Thin: Everything else in Section 3 rests on exactly one source: the ISFM guideline's specific 75–150 mL/1–3 day figure and its apparent lack of an attached evidence grade [1]; the AAHA guideline's bare existence and general scope, since its CKD-specific content is unread [2]; and each of the three contrast RCTs (vitamin E [5], N-acetylcysteine [6], Renaltec [7]), none of which has yet been corroborated by a second, independent trial of the same intervention.
Rescoped from class 3: None in this report. Every proposition here is a named guideline's stated text, a registry's record count, or a measured trial finding — none asks what a person would do.
Out of scope: CPT descriptors (AMA-licensed). Veterinary payer, HCPCS, or fee-schedule data — already established at the domain-dossier level as structurally unreachable by any connector in this repo, not re-attempted here since this report's section is clinical evidence, not reimbursement. MAUDE narratives (no connector exists). Non-US guideline bodies beyond ISFM and AAHA — neither IRIS's own separate treatment-recommendations document nor any non-US CKD guideline was pursued as a numbered source here (see next paragraph for IRIS specifically).
Not searched vs. not found, and one document seen but not citable: The six subcutaneous-fluid trial query strings above were searched and returned nothing — a stronger negative than "not searched," though it does not rule out a trial existing under terminology none of the six strings captured. AAHA's feline-CKD-specific fluid-therapy content was not retrieved — blocked by the publisher (HTTP 403), not searched-and-absent. IRIS's own current guideline document, "Treatment Recommendations for CKD in Cats (2023)," was fetched and read in full this pass (via iris-kidney.com's search-indexed PDF path, redirected to a Squarespace-hosted file) — a genuine retrieval success the domain dossier's own prior attempt did not achieve (it 404'd on a guessed URL). Its dehydration-management text specifies fluid composition (low-sodium, ~30–40 mmol/L, with ~13 mmol/L added potassium, naming Normosol-M or 5% dextrose plus 0.18% NaCl with added KCl as examples) rather than ISFM's specific volume-and-frequency figure, for Stage 3–4 cats needing "maintenance fluids administered routinely." That content is not entered above as a numbered finding because the document carries no PMID, DOI, ISBN, or any other identifier in this report's closed vocabulary — a website-hosted, non-journal-published guideline PDF is a structural gap in citability under this report's own rule, not a retrieval failure, and it is named here rather than silently omitted.
[inference] Three independently designed, controlled trials of other feline-CKD interventions appearing in the literature within roughly the same two-year window that returned zero trials of subcutaneous fluid therapy suggests the gap is specific to this intervention rather than a general reluctance to run feline CKD trials — this is my own reading of the pattern across [1]–[7], not a conclusion stated by any one of them.
| Proposition | Evidence class | Resolvable identifier | Dossier section |
|---|---|---|---|
| The ISFM Consensus Guidelines recommend repeated subcutaneous fluid therapy of 75–150 mL every 1–3 days for cats, most commonly at IRIS CKD stages 3–4, administered on an outpatient basis or by owners at home | 2 — published finding | PMID 26936494 (PMC11148907) | 4. Standard of care & clinical evidence |
| The 2024 AAHA Fluid Therapy Guidelines for Dogs and Cats is a peer-reviewed practice guideline published 2024-07-01 in the Journal of the American Animal Hospital Association | 2 — published finding | PMID 38885492; DOI 10.5326/jaaha-ms-7444 | 4. Standard of care & clinical evidence |
| 205 of 405 (50.6%) caregivers of cats with CKD surveyed in Portugal administered subcutaneous fluid therapy at home, with significantly higher use among cats at later IRIS CKD stages (P<0.05) | 2 — published finding | PMID 41398709 | 5. Reference products |
| A double-blind, placebo-controlled trial of vitamin E supplementation in 34 cats with CKD over 24 weeks found no effect on survival time | 2 — published finding | PMID 38987749 | 4. Standard of care & clinical evidence |
| A double-blind, placebo-controlled trial of intravenous N-acetylcysteine in 50 cats with azotemic CKD found significantly lower day-8 creatinine (4.01 vs 6.44 mg/dL, P<0.001) in the treatment arm versus placebo | 2 — published finding | PMID 41630014 | 4. Standard of care & clinical evidence |